Moderna, Inc. has extended its rally to 150% intraday, lifting the company's market capitalization above $60 bln after Moderna and Merck announced successful melanoma vaccine research. Merck advanced more than 12%, BioNTech SE rose over 24%, while the Nasdaq Biotechnology Index climbed more than 5%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.